DDInter202 DDInter899
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Bexarotene {u} (Compound) resembles {v} (Compound) Tamibarotene
Bexarotene {u} (Compound) treats {v} (Disease) hematologic cancer
Bexarotene {u} (Compound) binds {v} (Gene) RXRG
Bexarotene {u} (Compound) is included by {v} (Pharmacologic Class) Retinoids
Bexarotene {u} (Compound) causes {v} (Side Effect) Hypocholesterolaemia
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Griseofulvin
Bexarotene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amlodipine
Bexarotene {u} may lead to a major life threatening interaction when taken with {v} Cytarabine
Bexarotene (Compound) resembles Tamibarotene (Compound)
Bexarotene (Compound) treats hematologic cancer (Disease)
Bexarotene (Compound) binds RXRG (Gene)
Bexarotene (Compound) is included by Retinoids (Pharmacologic Class)
Bexarotene (Compound) causes Hypocholesterolaemia (Side Effect)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Griseofulvin
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Amlodipine
Bexarotene may lead to a major life threatening interaction when taken with Cytarabine